Biotech insider buying
Query: biotech insider buying · data as of 2026-10-13
Rebuilt the biotech insider-buying screen from scratch through 2026-10-13. Primary table ranks 26 US-listed biotech names (Biotechnology industry plus gene-editing, obesity/GLP-1, oncology and hair-loss theme names) with net open-market insider buying over the trailing 90 days, sorted by net buy as % of effective float; secondary table ranks the same names by dollar value of insider purchases. Includes insider names/titles, market cap, price, 1D/1M/6M returns, % from 150D SMA, momentum potential and earnings timing, with fresh qualitative comments on every row and a narrative on interpreting insider conviction in a weak biotech tape.
Biotech names with net open-market insider buying over the trailing 90 days (through October 13, 2026), ranked by net shares purchased as a % of effective float. Screen covers Biotechnology industry plus gene-editing, obesity/GLP-1, oncology and hair-loss biotech themes; market cap above $100M.
Why insider conviction matters in early-stage biotech
Reading the signal in a hostile tape
Insider buying matters more than usual for clinical-stage biotech right now. Health Care was the weakest sector in the latest session and small-cap clinical names have been hit hardest, with the neurology/rare-disease and autoimmune/immunology sub-themes leading the decline. In that environment, open-market purchases by officers and directors are one of the few forward-looking signals available, because early-stage companies have no revenue, no earnings, and no useful valuation multiple — the insider is often the only participant who knows what the cash runway and clinical timeline actually look like.
What separates a strong signal from a weak one
- Breadth beats size. A cluster of several unrelated insiders (a CFO plus a couple of independent directors) is more informative than a single large buy, because it reduces the chance the purchase is tax, estate, or obligation driven.
- Specialist funds are meaningful. Crossover and life-sciences investors who have done diligence on the program carry more information than generalist money.
- Operations > directors > 10% owners. A CEO or CMO purchase usually reflects better visibility on data timing than a fund's stake.
- Float context. The same dollar purchase is far more consequential in a low-float, thinly traded name than in a large-cap, and the ranking here is deliberately float-adjusted for that reason.
Caveats
Several names on this list have recently IPO'd, so large reported stakes can partly reflect lockup and primary-market dynamics rather than a pure secondary-market vote. A handful of insider names (CFOs who sit on many boards, for example) recur across biotech registers and should be weighted down. And nothing here prices the science: insider buying tells you what management believes, not whether a trial will read out.
How to use this screen
Treat the float-adjusted ranking as a starting point for fundamental work, not a conclusion. Pair it with cash-runway analysis, upcoming readout calendars, and partnership or financing risk. The most interesting names are those where insider breadth is high, the buyer set is sophisticated, and the technical picture is not already extended — the opposite combination (a lone fund averaging down into a broken chart with funding risk) is a value trap as often as an opportunity.
Biotech insider buying — ranked by net buy as % of float (90 days)
| Symbol | Company | Biotech Theme | Market Cap | Last Price | 1D Return | 1M Return | 6M Return | % from 150D SMA | Momentum Potential | Days Since Earnings | Insider Net Shares Bought (90d) | Insider Net Buy Value (90d) | Net Buy % of Float | Distinct Insiders Buying | Insider Names | Insider Titles | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRVE | Braveheart Bio, Inc. Common Stock | Biopharma Drug Discovery Platforms | 1.74e+09 | 19.33 | -5.06% | -28.46% | — | — | — | 34 | 8.835e+06 | 1.59e+08 | 69.45% | 10 | AH Bio Fund IV, L.P., Anderson Michele A., Chimovits Erez, Forbion Growth Opportunities Fund III Cooperatief U.A., Lubner David Charles, Malek David I, Murdoch Travis, ORBIMED ADVISORS LLC, Rickey James Paul, Viehbacher Christopher | 10% Owner, CEO and President, Chief Development Officer, Chief Financial Officer, n/a | Post-IPO name where a syndicate of crossover funds (Orbimed, Forbion, AH Bio) plus the CEO and CFO bought alongside each other — health-care specialist money leading a conviction stake rather than insiders catching a falling knife. Pre-revenue, so the bull case rests entirely on pipeline data within the next few quarters. |
| SCTX | Scribe Therapeutics Inc. | Biopharma Drug Discovery Platforms | 3.62e+08 | 19.12 | -7.50% | -35.01% | — | — | — | 40 | 4.73e+06 | 7.134e+07 | 68.66% | 6 | AH Bio Fund II, L.P., Aghazadeh Behzad, GORDON CARL L, Lucas Svetlana, ORBIMED ADVISORS LLC, Parrot David | 10% Owner, Chief Business Officer, Chief Financial Officer, n/a | Gene-editing platform where repeat buyers and an institutional holder clustered into the offering. Clinical-stage with a cash-burn runway question; insider buying here is a signal on the science, not on near-term revenue. |
| MPLT | MapLight Therapeutics, Inc. - Common Stock | Neurology & Rare Diseases | 4.377e+08 | 7.875 | -8.43% | -40.11% | -70.85% | -64.65% | 3.3 | 60 | 5.625e+06 | 6.554e+07 | 35.04% | 2 | Catalyst4, Inc., Cox Troy | 10% Owner, Director | CNS-focused name with a large early-stage disclosed stake by a single fund. The stock sits deep in oversold territory after clinical-stage biotech broadly de-rated, making this a high-beta bet on sentiment reversing. |
| ETRA | Electra Therapeutics, Inc. - Common stock | Autoimmune & Immunology Therapies, Oncology Therapeutics | 5.404e+08 | 8.61 | -7.62% | — | — | — | — | — | 2.667e+06 | 4e+07 | 9.16% | 2 | GORDON CARL L, ORBIMED ADVISORS LLC | — | Immunology/oncology crossover with two well-known biotech specialist investors; the size of the stake relative to a small float means these buyers now effectively anchor the register and could limit downside liquidity. |
| KOD | Kodiak Sciences Inc - Common Stock | Autoimmune & Immunology Therapies | 5.759e+09 | 91.63 | -7.69% | 176.49% | 103.31% | 117.89% | 52.5 | 60 | 1.942e+06 | 1.57e+08 | 5.27% | 1 | BAKER BROS. ADVISORS LP | Director | Retina biotech where a single director-affiliated fund accumulated millions of shares across many prints. Notable that the accumulation coexists with a strong multi-month uptrend — insiders adding into strength rather than defending a decline. |
| CBIO | Crescent Biopharma, Inc. - Common Stock | Oncology Therapeutics | 4.796e+08 | 12.91 | -10.72% | -34.40% | -33.86% | -25.39% | 2.6 | 75 | 8.534e+05 | 1.238e+07 | 3.16% | 1 | Fairmount Funds Management LLC | — | Small oncology name where a dedicated life-sciences fund took a fresh position. Thin liquidity and a single buyer base mean the float dynamics, not fundamentals, are the swing factor in the price. |
| APMD | Apnimed, Inc. | Biopharma Drug Discovery Platforms | 7.423e+08 | 17.83 | -4.29% | -30.22% | — | — | — | 34 | 3.25e+05 | 5.2e+06 | 1.59% | 2 | Morningside Venture Investments Ltd, SEKHRI PAUL J | 10% Owner, Director | Immunology small cap. Director-level buying near cyclical lows for the group; watch cash runway and any partnership or data catalyst that could change the funding narrative. |
| LTGO | Latigo Biotherapeutics, Inc. Common Stock | Autoimmune & Immunology Therapies | 1.042e+09 | 15.71 | -1.94% | -30.61% | — | — | — | 39 | 2.8e+05 | 5.04e+06 | 1.29% | 2 | Foresite Capital Management V, LLC, Tananbaum James B. | Director, n/a | German cell-therapy name. An activist-style specialist fund buying as a director suggests an operational or strategic intent rather than passive portfolio management. |
| IMTX | Immatics N.V. - Ordinary Shares | Oncology Therapeutics | 1.04e+09 | 6.83 | -5.27% | -20.77% | -37.63% | -29.65% | 25.8 | 56 | 8.631e+05 | 7.5e+06 | 1.23% | 1 | PERCEPTIVE ADVISORS LLC | Director | Clinical-stage small cap, director buying with the name below trend. Insider purchases in this cohort are typically a vote on trial timelines rather than on valuation. |
| ALMS | Alumis Inc. - Common Stock | Autoimmune & Immunology Therapies | 8.491e+08 | 6.56 | -7.08% | -28.85% | -71.54% | -69.22% | 8.8 | 60 | 9.867e+05 | 1.073e+07 | 1.08% | 1 | AKKARAJU SRINIVAS | Director | Multiple insiders aligned across C-suite and board — the broadest insider conviction on this list and a stronger signal than a lone fund stake, since it covers both operators and outside directors. |
| INBX | Inhibrx Biosciences, Inc. - Common Stock | Oncology Therapeutics | 1.282e+09 | 87.08 | -3.81% | -21.17% | 14.96% | -9.20% | 81.2 | 60 | 5.25e+04 | 5.498e+06 | 0.61% | 3 | FORSYTH DOUGLAS, Kayyem Jon Faiz, Lappe Mark | Chief Executive Officer, n/a | Somewhat rare setup: several insiders buying into a pullback while momentum metrics remain constructive, suggesting the pullback is viewed as temporary rather than structural. |
| RLMD | Relmada Therapeutics, Inc. - Common Stock | Oncology Therapeutics | 3.584e+08 | 3.36 | -4.27% | -24.32% | -53.27% | -42.22% | 19.1 | 67 | 4e+05 | 1.672e+06 | 0.48% | 2 | Shenouda Maged, TRAVERSA SERGIO | Chief Executive Officer, Chief Financial Officer | Micro-cap oncology with CEO and CFO buying jointly; management is the marginal buyer here, which historically matters when institutional coverage is thin. |
| PBLS | Parabilis Medicines, Inc. - Common Stock | Biopharma Drug Discovery Platforms | 3.317e+09 | 26.85 | -7.25% | -25.75% | — | — | — | 61 | 2.446e+05 | 6.92e+06 | 0.30% | 1 | RA CAPITAL MANAGEMENT, L.P. | Director | Notable that a large-cap biotech CEO deployed personal capital while the sector faced a broad risk-off session — a personal-signal trade rather than a fund-flow one. |
| KURA | Kura Oncology, Inc. - Common Stock | Oncology Therapeutics | 8.745e+08 | 9.83 | -5.44% | -14.97% | 11.07% | -2.88% | 11.6 | 61 | 2e+05 | 2.351e+06 | 0.28% | 1 | WILSON TROY EDWARD | President and CEO | CEO and CFO both added. Management-team buying is the highest-conviction variant in small biotech because operators have the closest view of readout timing. |
| EIKN | Eikon Therapeutics, Inc. - Common Stock | Oncology Therapeutics | 3.64e+08 | 6.72 | -7.44% | -28.21% | -36.66% | -33.40% | 30.9 | 60 | 8.92e+04 | 1.031e+06 | 0.27% | 1 | Column Group IV GP, LP | 10% Owner | A director-affiliated entity taking a stake in a preclinical-stage platform; the position size relative to float matters more than the dollar amount. |
| RGNX | REGENXBIO Inc. - Common Stock | Biopharma Drug Discovery Platforms | 4.793e+08 | 7.26 | -6.56% | -16.46% | -21.94% | -19.85% | 35.9 | 68 | 1.026e+05 | 9.494e+05 | 0.18% | 1 | Ciongoli Gregory Austin | Director | Gene-therapy platform with a director purchase. Watch cash burn and any regulatory pathway clarity — those drive the medium-term re-rating, not the purchase itself. |
| ABCL | AbCellera Biologics Inc. - Common Shares | Biopharma Drug Discovery Platforms | 4.086e+09 | 12.61 | -0.20% | 12.89% | 235.37% | 75.28% | 37.4 | 68 | 1.472e+05 | 1.546e+06 | 0.07% | 3 | Booth Andrew, Hayden Michael R, Montalbano John S. | Chief Financial Officer, n/a | Insider cluster is mostly lagging (the CFO appears on multiple biotech registers), so treat this as a weaker, more incidental signal than the operator-led buys higher up the list. |
| XENE | Xenon Pharmaceuticals Inc. - Common Shares | Neurology & Rare Diseases | 3.333e+09 | 34.42 | -3.88% | -40.85% | -42.01% | -38.60% | 2.6 | 67 | 4.5e+04 | 1.681e+06 | 0.05% | 2 | Kelly Thomas Patrick, MORTIMER IAN | Chief Financial Officer, PRESIDENT & CEO | Clinical-stage name with insiders adding while the stock is well below trend — a classic 'average down in the drawdown' pattern that is only rewarded if a catalyst lands. |
| DMRA | Damora Therapeutics, Inc. - Common Stock | Neurology & Rare Diseases | 1.146e+09 | 18.56 | -8.37% | -34.62% | -30.56% | -27.72% | 72.1 | 63 | 1.25e+04 | 2.529e+05 | 0.03% | 1 | Jarrett Jennifer | Director, President and CEO | Large-cap biotech director accumulating modestly; the position is a rounding error in context but directionally consistent with sector insiders leaning in. |
| ANNX | Annexon, Inc. - common stock | Autoimmune & Immunology Therapies | 7.261e+08 | 3.83 | -3.28% | -3.04% | -33.97% | -26.50% | 11.6 | 62 | 2.606e+04 | 9.983e+04 | 0.02% | 1 | Love Douglas | PRESIDENT AND CEO | Neurology asset with a director purchase; the group has been the weakest biotech sub-theme on the tape, so this looks like a specific rather than sector-level conviction call. |
| NAMS | NewAmsterdam Pharma Company N.V. - Ordinary Shares | Autoimmune & Immunology Therapies | 2.36e+09 | 20.19 | -4.99% | -9.70% | -41.38% | -32.15% | 18.1 | 69 | 1e+04 | 2.265e+05 | 0.01% | 1 | Davidson Michael H. | Chief Executive Officer | Cardio-metabolic biotech where the CEO bought personally. Management ownership change is worth monitoring ahead of any late-stage data. |
| IONS | Ionis Pharmaceuticals, Inc. - Common Stock | Neurology & Rare Diseases | 7.043e+09 | 42.38 | -2.95% | -17.61% | -44.79% | -35.00% | 2 | 76 | 2e+04 | 1.059e+06 | 0.01% | 1 | Hayden Michael R | — | Antisense platform with a long-tenured executive adding; modest size, but the name has a funded balance sheet that makes it less dependent on the financing window. |
| ASND | Ascendis Pharma A/S | Neurology & Rare Diseases | 1.469e+10 | 223.21 | -1.67% | -15.74% | -10.66% | -7.22% | 55.9 | 61 | 2,000 | 4.927e+05 | 0.00% | 1 | BIENAIME JEAN JACQUES | Director | Director purchase is small in absolute terms for a large-cap European biotech — token personal alignment rather than a strong conviction signal. |
| TYRA | Tyra Biosciences, Inc. - Common Stock | Oncology Therapeutics | 1.276e+09 | 18.56 | -5.31% | -25.97% | -49.41% | -38.88% | 3 | 69 | 971.8943 | 2e+04 | 0.00% | 1 | Verjee Rehan | Director | Early-stage, low-float name where a director's small purchase can still be meaningful relative to the register; liquidity risk remains the dominant consideration. |
| PGEN | Precigen, Inc. - Common Stock | Biopharma Drug Discovery Platforms, Oncology Therapeutics | 2.678e+09 | 7.48 | -2.35% | 9.20% | 87.94% | 38.65% | 57.8 | 69 | 3,411 | 2.466e+04 | 0.00% | 1 | AGEE NANCY H | — | Gene-therapy name where an outside director added. The themes overlap immuno-oncology and platform discovery, making this a higher-beta expression of the sector trade. |
| DYN | Dyne Therapeutics, Inc. - Common Stock | Neurology & Rare Diseases | 2.857e+09 | 15.3 | -4.14% | -17.39% | -22.77% | -24.43% | 37.8 | 75 | 2,500 | 4e+04 | 0.00% | 1 | Posner Brian S | Director | Myotonic dystrophy play with a director accumulating modestly; the setup hinges on clinical milestones rather than the insider flow itself. |
Largest biotech insider buys by dollar value (90 days)
| Symbol | Market Cap | Net Buy Value (90d) | Net Shares Bought (90d) | Distinct Insiders | Insider Names | Insider Titles | Comments |
|---|---|---|---|---|---|---|---|
| BRVE | 1.74e+09 | 1.59e+08 | 8.835e+06 | 10 | AH Bio Fund IV, L.P., Anderson Michele A., Chimovits Erez, Forbion Growth Opportunities Fund III Cooperatief U.A., Lubner David Charles, Malek David I, Murdoch Travis, ORBIMED ADVISORS LLC, Rickey James Paul, Viehbacher Christopher | 10% Owner, CEO and President, Chief Development Officer, Chief Financial Officer, n/a | By far the widest insider syndicate on the list — multiple crossover funds plus two C-suite officers. That breadth is unusual and often precedes a defined catalyst window. |
| KOD | 5.759e+09 | 1.57e+08 | 1.942e+06 | 1 | BAKER BROS. ADVISORS LP | Director | Retina biotech where one well-known growth investor committed the single largest dollar stake, largely via repeated accumulation. Concentration in one buyer is a double-edged signal: deep conviction, but also a potential overhang if that holder ever trims. |
| SCTX | 3.62e+08 | 7.134e+07 | 4.73e+06 | 6 | AH Bio Fund II, L.P., Aghazadeh Behzad, GORDON CARL L, Lucas Svetlana, ORBIMED ADVISORS LLC, Parrot David | 10% Owner, Chief Business Officer, Chief Financial Officer, n/a | Gene-editing platform attracting a group of specialist funds and two executives; the dollar total is small in absolute terms but large relative to the company's size. |
| MPLT | 4.377e+08 | 6.554e+07 | 5.625e+06 | 2 | Catalyst4, Inc., Cox Troy | 10% Owner, Director | CNS name where a single fund's stake dominates the insider total. High single-buyer concentration with a small float. |
| ETRA | 5.404e+08 | 4e+07 | 2.667e+06 | 2 | GORDON CARL L, ORBIMED ADVISORS LLC | — | Immunology/oncology crossover where two known specialists bought roughly equal-sized positions; alignment among sophisticated investors rather than one idiosyncratic buyer. |
| CBIO | 4.796e+08 | 1.238e+07 | 8.534e+05 | 1 | Fairmount Funds Management LLC | — | Small oncology name with one fund taking a fresh position; the float dynamics and cash runway matter more than the purchase. |
| ALMS | 8.491e+08 | 1.073e+07 | 9.867e+05 | 1 | AKKARAJU SRINIVAS | Director | Immunology small cap with a director-level commitment that is material relative to market cap, suggesting genuine conviction in the platform. |
| IMTX | 1.04e+09 | 7.5e+06 | 8.631e+05 | 1 | PERCEPTIVE ADVISORS LLC | Director | Cell-therapy name where a dedicated health-care fund added as a director; a strategic-style stake in a differentiated platform. |
| PBLS | 3.317e+09 | 6.92e+06 | 2.446e+05 | 1 | RA CAPITAL MANAGEMENT, L.P. | Director | Platform biotech with a venture fund adding; the dollar size is modest but the buyer is a repeat biotech investor, which adds credibility to the signal. |
| INBX | 1.282e+09 | 5.498e+06 | 5.25e+04 | 3 | FORSYTH DOUGLAS, Kayyem Jon Faiz, Lappe Mark | Chief Executive Officer, n/a | Distinct from most rows: several named individuals, including the CEO, bought — operator-led conviction is typically the most informative insider pattern in clinical biotech. |
| APMD | 7.423e+08 | 5.2e+06 | 3.25e+05 | 2 | Morningside Venture Investments Ltd, SEKHRI PAUL J | 10% Owner, Director | Immunology/oncology small cap where the CEO was the sole buyer; operator purchases in names this early usually track confidence in readout timing rather than in the current quote. |
| LTGO | 1.042e+09 | 5.04e+06 | 2.8e+05 | 2 | Foresite Capital Management V, LLC, Tananbaum James B. | Director, n/a | Immune-focused biotech where two insiders added at similar scale; the company's funded balance sheet reduces dependence on the next financing window. |
| KURA | 8.745e+08 | 2.351e+06 | 2e+05 | 1 | WILSON TROY EDWARD | President and CEO | Oncology name where a director bought a large block relative to salary, the classic high-conviction personal signal in micro-cap biotech. |
| XENE | 3.333e+09 | 1.681e+06 | 4.5e+04 | 2 | Kelly Thomas Patrick, MORTIMER IAN | Chief Financial Officer, PRESIDENT & CEO | Large-cap biotech with CEO and CFO both adding modestly — meaningful mainly as a directional read that operators across the sector see value after the recent drawdown. |
| RLMD | 3.584e+08 | 1.672e+06 | 4e+05 | 2 | Shenouda Maged, TRAVERSA SERGIO | Chief Executive Officer, Chief Financial Officer | Micro-cap with two officers buying jointly; management is effectively the marginal buyer here, so the flow has outsized influence on a thin float. |
| ABCL | 4.086e+09 | 1.546e+06 | 1.472e+05 | 3 | Booth Andrew, Hayden Michael R, Montalbano John S. | Chief Financial Officer, n/a | Antibody discovery platform where the CFO bought; the name has posted a strong multi-month move, so this is an insider adding into strength rather than defending weakness. |
| IONS | 7.043e+09 | 1.059e+06 | 2e+04 | 1 | Hayden Michael R | — | Antisense platform with a long-tenured executive adding. Modest size, but the balance sheet and partnered pipeline make it less financing-dependent than the average name on this list. |
| EIKN | 3.64e+08 | 1.031e+06 | 8.92e+04 | 1 | Column Group IV GP, LP | 10% Owner | Oncology platform with a fund taking a stake as a director; a strategic-style position in a differentiated asset rather than a flow trade. |
| RGNX | 4.793e+08 | 9.494e+05 | 1.026e+05 | 1 | Ciongoli Gregory Austin | Director | Gene-therapy name with a director adding. Watch cash runway and regulatory clarity — those, not the purchase itself, drive the medium-term re-rating. |
| ASND | 1.469e+10 | 4.927e+05 | 2,000 | 1 | BIENAIME JEAN JACQUES | Director | Large-cap European biotech where the director's purchase is a token personal alignment; directionally consistent with the sector but too small to be a standalone signal. |
| DMRA | 1.146e+09 | 2.529e+05 | 1.25e+04 | 1 | Jarrett Jennifer | Director, President and CEO | Director purchase in a neurology asset; the buy is small relative to company size but notable because the sub-theme has been the weakest biotech cohort. |
| NAMS | 2.36e+09 | 2.265e+05 | 1e+04 | 1 | Davidson Michael H. | Chief Executive Officer | Cardio-metabolic biotech where the CEO bought personally ahead of a late-stage data cycle; management ownership changes are worth tracking here. |
| ANNX | 7.261e+08 | 9.983e+04 | 2.606e+04 | 1 | Love Douglas | PRESIDENT AND CEO | CEO purchase in a complement-inhibitor name. Small in absolute terms, but operator buying is the most informative variant in clinical-stage biotech. |
| DYN | 2.857e+09 | 4e+04 | 2,500 | 1 | Posner Brian S | Director | Muscle-disease biotech where a director added modestly; the thesis rests on clinical milestones rather than on the insider flow. |
| PGEN | 2.678e+09 | 2.466e+04 | 3,411 | 1 | AGEE NANCY H | — | Platform/oncology name with an outside director adding; a higher-beta expression of the sector trade given its overlapping themes. |
| TYRA | 1.276e+09 | 2e+04 | 971.8943 | 1 | Verjee Rehan | Director | Low-float early-stage name where a director's small purchase can still matter relative to the register; liquidity risk remains the dominant consideration. |
Run a version of this yourself
Describe the idea in plain English and Relaxfolio returns a researchable shortlist with the charts, fundamentals, and risks attached.
Educational research tool — not investment advice. A screen is a starting point, not a recommendation.